Evogene (NASDAQ:EVGN) Director Leon Recanati Purchases 460,000 Shares of Stock

Evogene Ltd. (NASDAQ:EVGN) Director Leon Recanati bought 460,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was acquired at an average cost of $0.64 per share, with a total value of $294,400.00. Following the completion of the purchase, the director owned 1,343,886 shares of the company’s stock, valued at approximately $860,087.04. This trade represents a 52.04% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Evogene Price Performance

Shares of Evogene stock opened at $0.65 on Friday. The company has a market capitalization of $5.68 million, a P/E ratio of -0.47 and a beta of 1.40. The business has a 50-day moving average of $0.53 and a two-hundred day moving average of $0.73. Evogene Ltd. has a 1 year low of $0.37 and a 1 year high of $1.50.

Evogene (NASDAQ:EVGN) last released its quarterly earnings data on Saturday, May 16th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.33). Evogene had a negative net margin of 638.12% and a negative return on equity of 158.82%. The business had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.35 million.

Institutional Trading of Evogene

Institutional investors have recently modified their holdings of the company. Jane Street Group LLC grew its holdings in shares of Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after buying an additional 12,387 shares in the last quarter. XTX Topco Ltd bought a new stake in Evogene in the 4th quarter valued at approximately $25,000. Finally, Citadel Advisors LLC lifted its stake in Evogene by 169.4% in the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 36,206 shares in the last quarter. 10.40% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Evogene in a report on Wednesday, July 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Evogene presently has an average rating of “Sell”.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.